JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB323747

Anti-IFITM2+IFITM3 antibody [EPR28942-88]

Be the first to review this product! 리뷰 제출

|

(0 출판물)

Rabbit Recombinant Monoclonal IFITM2 antibody. Suitable for Flow Cyt (Intra), ICC/IF, WB and reacts with Transfected cell line - Human, Human samples.
7 이미지
Flow Cytometry (Intracellular) - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)
  • Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)

Flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized HeLa (human cervical adenocarcinoma epithelial cell) treated with 10ng/mL IFN-alpha 1 for 16 hours (Green) / Untreated HeLa (Magenta) cells labelling IFITM2+IFITM3 with ab323747 at 1/50 dilution (1 ug) / Magenta and Green compared with a Rabbit monoclonal IgG (ab172730) (Black) and Grey isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody).

Goat Anti-Rabbit IgG (Alexa Fluor® 488, ab150081) at 1/5000 dilution was used as the secondary antibody.

Immunocytochemistry/ Immunofluorescence - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)

Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized HeLa (human cervical adenocarcinoma epithelial cell) cells labelling IFITM2+IFITM3 with ab323747 at 1/250 (2.004 ug/ml) dilution, followed by ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed antibody at 1/ 1000 2ug/ml dilution (Green).

Confocal image showing membranous and cytoplasmic staining in HeLa cell line treated with IFN alpha 1 (10ng/ml) for 16h, and weak cytoplasmic staining in HeLa cell line (shown in green). The counterstain was observed in magenta. Nuclear DNA was labelled with DAPI (shown in blue). Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).

ab195889 Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/ 200 2.5ug/ml dilution (Magenta). The Nuclear counterstain was DAPI (Blue).

Secondary antibody only control : Secondary antibody is ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed at 1/ 1000 2ug/ml dilution.

Flow Cytometry (Intracellular) - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)
  • Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)

Flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized A549 (human lung carcinoma epithelial cell) treated with 10ng/mL IFN-alpha 1 for 16 hours (Green) / Untreated A549 (Magenta) cells labelling IFITM2+IFITM3 with ab323747 at 1/50 dilution (1 ug) / Magenta and Green compared with a Rabbit monoclonal IgG (ab172730) (Black) and Grey isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody).

Goat anti-Rabbit IgG (Alexa Fluor® 647, ab150083) at 1/5000 dilution was used as the secondary antibody.

Flow Cytometry (Intracellular) - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)
  • Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)

Flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized Isotype (upper left) / 293T (human embryonic kidney epithelial cell) cells transfected with an empty expression vector containing a Myc tag (upper middle) / 293T cells transfected with a IFITM1 expression vector containing a GFP tag (down left) / 293T cells transfected with a IFITM2 expression vector containing a GFP tag (down middle) / 293T cells transfected with a IFITM3 expression vector containing a GFP tag(down right) cells labelling IFITM2+IFITM3 with ab323747 at 1/5000 dilution (0.01 ug) compared with a Rabbit monoclonal IgG (ab172730) / Left isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody).

Goat anti-Rabbit IgG (Alexa Fluor® 647, ab150083) at 1/5000 dilution was used as the secondary antibody.

Immunocytochemistry/ Immunofluorescence - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)

Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized A549 (human lung carcinoma epithelial cell) cells labelling IFITM2+IFITM3 with ab323747 at 1/250 (2.004 ug/ml) dilution, followed by ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed antibody at 1/ 1000 2ug/ml dilution (Green).

Confocal image showing membranous and cytoplasmic staining in A549 cell line treated with IFN alpha (1000 U/ml) for 24h, and weak staining in A549 cell line (shown in green). The counterstain was observed in magenta. Nuclear DNA was labelled with DAPI (shown in blue). Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).

ab195889 Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/ 200 2.5ug/ml dilution (Magenta). The Nuclear counterstain was DAPI (Blue).

Secondary antibody only control : Secondary antibody is ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed at 1/ 1000 2ug/ml dilution.

Western blot - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)
  • WB

Supplier Data

Western blot - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID : 34078739; PMID : 34321474; PMID : 30643282).

The expression of IFITM2 and IFITM3 is up-regulated in response to IFN alpha 1 or IFN beta treatment (PMID : 34078739; PMID : 34321474; PMID : 30643282).

In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) staining at 1/200000 dilution.

Exposure time : Lanes 1-4 : 15 seconds; Lanes 5-6 : 5 seconds

All lanes:

Western blot - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (ab323747) at 1/1000 dilution

Lanes 1 and 3:

Untreated A549 (human lung carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 2:

A549 treated with 1000U/ml IFN alpha 1 for 24 hours whole cell lysate at 20 µg

Lane 4:

A549 treated with 1000U/ml IFN beta 1 for 24 hours whole cell lysate at 20 µg

Lane 5:

Untreated HeLa (human cervical adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Lane 6:

HeLa treated with 10ng/ml IFN alpha 1 for 16 hours whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/ko/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Observed band size: 15 kDa,36 kDa

false

Western blot - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)
  • WB

Supplier Data

Western blot - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (AB323747)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

Negative control : Daudi

The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID : 34078739; PMID : 34321474; PMID : 30643282).

Lane 3 is incubated with Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 and lanes 1-2 are incubated with Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/20000.

In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) staining at 1/200000 dilution.

All lanes:

Western blot - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (ab323747) at 1/1000 dilution

Lane 1:

THP-1 (human monocytic leukemia monocyte) whole cell lysate at 20 µg

Lane 2:

Daudi (human Burkitts lymphoma lymphoblast) whole cell lysate at 20 µg

Lane 3:

Human liver tissue lysate at 20 µg

Secondary

Lanes 1 - 2:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/ko/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Lane 3:

Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

Observed band size: 15 kDa,36 kDa

false

Exposure time: 70s

주요 정보

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR28942-88

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

ICC/IF, Flow Cyt (Intra), WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity 정보

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/50", "FlowCytIntra-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/250", "ICCIF-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" }, "Transfected cell line - Human": { "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/5000", "FlowCytIntra-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

제품 세부 정보

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

특성 및 보관 정보

제형
Liquid
Purification 테크닉
Affinity purification Protein A
보관 버퍼
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
배송 시 보관 조건
Conditional Ambient
적절한 단기 보관 기간
1-2 weeks
적절한 단기 보관 조건
+4°C
적절한 장기 보관 조건
-20°C
분주 정보
Upon delivery aliquot
보관 정보
Avoid freeze / thaw cycle

제품 프로토콜

For this product, it's our understanding that no specific protocols are required. You can visit:

타겟 정보

IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol (PubMed : 26354436, PubMed : 33563656). Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) (PubMed : 26354436, PubMed : 33239446, PubMed : 33270927, PubMed : 33563656). Can inhibit : influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry (PubMed : 33563656). Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed : 26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed : 26354436).
See full target information IFITM2

Additional targets

IFITM3

대체 명칭 보기

Interferon-induced transmembrane protein 2, Dispanin subfamily A member 2c, Interferon-inducible protein 1-8D, DSPA2c, IFITM2, Interferon-induced transmembrane protein 3, Dispanin subfamily A member 2b, Interferon-inducible protein 1-8U, DSPA2b, IFITM3

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.
자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com